Mary Spellman, MD, FAAD, is the new Chief Medical Officer of Convoy Therapeutics, a biopharmaceutical company focused on unmet needs in the medical dermatology and aesthetics markets. Dr. Spellman has previously served as CMO of Revance Therapeutics and held senior positions at Biogen Idec and Novartis.
"Mary brings a wealth of experience in clinical development to Convoy, and we are proud to have her as a member of our executive management team as we enter the next exciting phase in the company's growth,” said John Muraski, PhD, CEO of Convoy. “Mary will be instrumental in overseeing all of our planned clinical studies for CycloPsorb and our other programs."
Dr. Spellman will work alongside Convoy's executive management team, all of whom bring decades of experience in the pharmaceutical and biotechnology industries, including John Muraski, PhD (CEO), David Loynd (CFO), Deborah Slee, PhD (VP of Research & Development), Ann Deren-Lewis, MBA (VP of Sales & Marketing), and Shep Bentley, RAC (VP of Regulatory Affairs).
CycloPsorb is a topical formulation of cyclosporine for psoriasis and eczema. The company is also the developer and Khalay HA, a topical hyaluronic acid filler for the rapid treatment of fine lines and wrinkles.